Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
ADRB2 154 PROPRANOLOL CHEMBL27 antagonist GuideToPharmacologyInteractions, TEND, DrugBank 16706406, 17628611, 16082424, 16177222, 11752352
ADRB2 154 SALMETEROL CHEMBL1263 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 12897749, 11516429, 10471277, 11752352, 11250877, 1359777
ADRB2 154 METIPRANOLOL CHEMBL1291 antagonist TdgClinicalTrial, TEND, DrugBank 2876128, 17139284, 17016423, 2885244, 2895037, 12967722
ADRB2 154 PIRBUTEROL CHEMBL1094966 agonist TTD, DrugBank 8945911, 7053311, 17260025, 11752352
ADRB2 154 PROCATEROL CHEMBL160519 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 15069780, 1684063, 11752352, 12428391, 1968366, 1682484
ADRB2 154 TERBUTALINE CHEMBL1760 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ADRB2 154 FUMAGILLIN CHEMBL32838 agonist TdgClinicalTrial, TTD
ADRB2 154 DOBUTAMINE CHEMBL926 agonist GuideToPharmacologyInteractions
ADRB2 154 CGP-12177 CHEMBL420746 antagonist GuideToPharmacologyInteractions
ADRB2 154 PROPAFENONE CHEMBL631 antagonist GuideToPharmacologyInteractions
ADRB2 154 CHEMBL1326499 CHEMBL1326499 antagonist GuideToPharmacologyInteractions
ADRB2 154 CHEMBL198059 CHEMBL198059 antagonist GuideToPharmacologyInteractions
ADRB2 154 PROPRANOLOL HYDROCHLORIDE CHEMBL1671 antagonist ChemblInteractions
ADRB2 154 EPINEPHRINE BITARTRATE CHEMBL1256958 agonist ChemblInteractions
ADRB2 154 CARVEDILOL PHOSPHATE CHEMBL1201167 antagonist ChemblInteractions
ADRB2 154 PROTOKYLOL HYDROCHLORIDE CHEMBL1200893 agonist ChemblInteractions
ADRB2 154 INDACATEROL MALEATE CHEMBL1789842 agonist ChemblInteractions
ADRB2 154 MEPHENTERMINE SULFATE CHEMBL1200996 agonist ChemblInteractions
ADRB2 154 ARFORMOTEROL TARTRATE CHEMBL1951071 agonist ChemblInteractions
ADRB2 154 ISOPROTERENOL SULFATE CHEMBL1200447 agonist ChemblInteractions
ADRB2 154 ESMOLOL HYDROCHLORIDE CHEMBL1201115 antagonist ChemblInteractions
ADRB2 154 AZD3199 CHEMBL3545103 agonist ChemblInteractions
ADRB2 154 NEBIVOLOL HYDROCHLORIDE CHEMBL1201731 antagonist ChemblInteractions
ADRB2 154 ATENOLOL CHEMBL24 antagonist GuideToPharmacologyInteractions, DrugBank 12795776
ADRB2 154 ALPRENOLOL CHEMBL266195 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 2859531, 2439825, 2871880
ADRB2 154 NADOLOL CHEMBL649 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 10433496, 17622774, 11752352, 1349493, 8574280, 7981009
ADRB2 154 BAMBUTEROL CHEMBL521589 agonist DrugBank, TTD 20012638, 11752352, 18065099, 8885698, 3262993, 12065188, 8223836
ADRB2 154 OXPRENOLOL CHEMBL546 antagonist TdgClinicalTrial, TEND, DrugBank 9509999, 17139284, 17016423, 7882570, 11311890
ADRB2 154 VOLANESORSEN SODIUM CHEMBL3544989 NCI 2557514
ADRB2 154 CARTEOLOL CHEMBL839 TdgClinicalTrial, TEND
ADRB2 154 SIBENADET CHEMBL82663 agonist TTD
ADRB2 154 LABETALOL CHEMBL429 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ADRB2 154 ABEDITEROL CHEMBL3039530 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
ADRB2 154 NORADRENALINE CHEMBL1356607 agonist GuideToPharmacologyInteractions, ChemblInteractions
ADRB2 154 EPHEDRINE CHEMBL211456 agonist GuideToPharmacologyInteractions
ADRB2 154 LK-204545 CHEMBL207802 antagonist GuideToPharmacologyInteractions
ADRB2 154 TRIHYDROXYARSENITE(III) CHEMBL1236189 antagonist GuideToPharmacologyInteractions
ADRB2 154 FOSFONET CHEMBL50300 antagonist GuideToPharmacologyInteractions
ADRB2 154 SOTALOL HYDROCHLORIDE CHEMBL1700 antagonist ChemblInteractions
ADRB2 154 DIPIVEFRIN HYDROCHLORIDE CHEMBL1200833 agonist ChemblInteractions
ADRB2 154 OLODATEROL HYDROCHLORIDE CHEMBL2105743 agonist ChemblInteractions
ADRB2 154 LABETALOL HYDROCHLORIDE CHEMBL1200323 antagonist ChemblInteractions
ADRB2 154 LY377604 CHEMBL2012520 antagonist ChemblInteractions
ADRB2 154 CARTEOLOL HYDROCHLORIDE CHEMBL1201002 antagonist ChemblInteractions
ADRB2 154 ISOPROTERENOL HYDROCHLORIDE CHEMBL1711 agonist ChemblInteractions
ADRB2 154 METIPRANOLOL HYDROCHLORIDE CHEMBL1200947 antagonist ChemblInteractions
ADRB2 154 OXPRENOLOL HYDROCHLORIDE CHEMBL1200745 antagonist ChemblInteractions
ADRB2 154 METAPROTERENOL SULFATE CHEMBL1200812 agonist ChemblInteractions, DrugBank, TTD 10490901, 2870555, 11752352, 10973730, 8760245, 3168573
ADRB2 154 RITODRINE CHEMBL785 agonist TdgClinicalTrial, TEND, DrugBank 11752352, 8059831, 11311067, 1332478, 12871140, 1976401
ADRB2 154 ISOPRENALINE CHEMBL1160723 agonist GuideToPharmacologyInteractions, DrugBank 12963495, 14752060, 15151902, 11752352, 15105445, 14656380, 10722
ADRB2 154 ARBUTAMINE CHEMBL1201251 agonist DrugBank 8723169
ADRB2 154 CARVEDILOL CHEMBL723 antagonist DrugBank, NCI, TdgClinicalTrial, PharmGKB, TEND, GuideToPharmacologyInteractions, ChemblInteractions 1712335, 14764656, 12360591, 12398570, 12835612
ADRB2 154 ARFORMOTEROL CHEMBL1363 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 18501650, 17594727, 11752352, 17472819, 16022567, 17352511, 14725487, 20406080
ADRB2 154 FENOTEROL CHEMBL32800 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 11752352, 11730729, 8911881, 16324695, 8777955, 6203844
ADRB2 154 PENBUTOLOL CHEMBL1290 partial agonist, antagonist TdgClinicalTrial, TEND, DrugBank 16716, 2446632, 11224195, 2189902, 8098761, 8982649
ADRB2 154 CLENBUTEROL CHEMBL49080 agonist TdgClinicalTrial, TEND, DrugBank, TTD 17449161, 1685013, 11752352, 1322047, 11720783, 12388476
ADRB2 154 CELIPROLOL CHEMBL27810 agonist DrugBank 17141277
ADRB2 154 NEBIVOLOL CHEMBL434394 antagonist DrugBank 12795776
ADRB2 154 DROXIDOPA CHEMBL2103827 agonist ChemblInteractions, DrugBank 18064417, 9666280, 19110970, 9464897, 7969507
ADRB2 154 CARAZOLOL CHEMBL324665 antagonist GuideToPharmacologyInteractions, DrugBank 10592235
ADRB2 154 BOPINDOLOL CHEMBL357995 partial agonist DrugBank 1979630, 1687398, 11752352, 1666931, 16574446, 1678274
ADRB2 154 BUPRANOLOL CHEMBL305380 antagonist GuideToPharmacologyInteractions, DrugBank 12606631
ADRB2 154 VILANTEROL CHEMBL1198857 agonist GuideToPharmacologyInteractions, DrugBank
ADRB2 154 ISOPROTERENOL CHEMBL434 PharmGKB, TdgClinicalTrial, NCI, TEND 10784181, 11358333, 14734046
ADRB2 154 RISPERIDONE CHEMBL85 PharmGKB
ADRB2 154 ALBUTEROL CHEMBL714 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, TTD
ADRB2 154 GLYCOPYRROLATE BROMIDE CHEMBL1201027 TdgClinicalTrial
ADRB2 154 BATEFENTEROL CHEMBL3039518 agonist TdgClinicalTrial, ChemblInteractions, TTD
ADRB2 154 MILVETEROL HYDROCHLORIDE CHEMBL2107356 agonist TTD
ADRB2 154 MILVETEROL CHEMBL1940832 agonist TdgClinicalTrial, ChemblInteractions, TTD
ADRB2 154 PSEUDOEPHEDRINE CHEMBL1590 TEND
ADRB2 154 GSK159802 CHEMBL3545087 agonist ChemblInteractions, TTD
ADRB2 154 BEDORADRINE SULFATE CHEMBL2218893 agonist TdgClinicalTrial, ChemblInteractions
ADRB2 154 ZINTEROL CHEMBL1243407 agonist GuideToPharmacologyInteractions
ADRB2 154 BETAXOLOL CHEMBL423 antagonist GuideToPharmacologyInteractions
ADRB2 154 LEVOBETAXOLOL CHEMBL1201274 antagonist GuideToPharmacologyInteractions
ADRB2 154 VILANTEROL TRIFENATATE CHEMBL1084172 agonist ChemblInteractions
ADRB2 154 LAS190792 CHEMBL3545272 agonist ChemblInteractions
ADRB2 154 LEVALBUTEROL TARTRATE CHEMBL2062258 agonist ChemblInteractions
ADRB2 154 FORMOTEROL FUMARATE DIHYDRATE CHEMBL2303638 agonist ChemblInteractions
ADRB2 154 ALBUTEROL SULFATE CHEMBL1201026 agonist ChemblInteractions
ADRB2 154 PROPAFENONE HYDROCHLORIDE CHEMBL1201063 antagonist ChemblInteractions
ADRB2 154 LEVALBUTEROL HYDROCHLORIDE CHEMBL1201061 agonist ChemblInteractions
ADRB2 154 NOREPINEPHRINE CHEMBL1437 agonist DrugBank 17139284, 17016423, 9666280, 18064417, 19110970, 11504801, 7969507, 9464897
ADRB2 154 MIRTAZAPINE CHEMBL654 binder DrugBank 10762339
ADRB2 154 DIPIVEFRIN CHEMBL1201262 agonist DrugBank 17597612, 11752352, 17622774, 17417877
ADRB2 154 PINDOLOL CHEMBL500 partial agonist, agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 1979630, 1687398, 11752352, 1666931, 16574446, 1678274
ADRB2 154 FORMOTEROL CHEMBL1256786 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 17594727, 11752352, 18686730, 7675115, 2544117, 16432501, 14720051, 9506248, 14662724, 1718682, 12090787
ADRB2 154 LEVOBUNOLOL CHEMBL1201237 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 2891463, 2892662, 11752352, 11572462, 7928182, 1351412, 6147147
ADRB2 154 BEVANTOLOL CHEMBL314010 antagonist DrugBank 17628611
ADRB2 154 INDACATEROL CHEMBL1095777 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 16022567
ADRB2 154 CARMOTEROL CHEMBL1094785 agonist ChemblInteractions, TTD
ADRB2 154 CHEMBL1240967 CHEMBL1240967 TdgClinicalTrial
ADRB2 154 DESIPRAMINE CHEMBL72 TdgClinicalTrial, TEND
ADRB2 154 TIMOLOL CHEMBL499 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND
ADRB2 154 EPINEPHRINE CHEMBL679 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND
ADRB2 154 FLUTICASONE CHEMBL1201396 agonist TTD
ADRB2 154 SALMETEROL XINAFOATE CHEMBL1082607 agonist ChemblInteractions, TTD
ADRB2 154 BUCINDOLOL CHEMBL321582 TdgClinicalTrial
ADRB2 154 MIRABEGRON CHEMBL2095212 agonist GuideToPharmacologyInteractions
ADRB2 154 SOLABEGRON CHEMBL208427 agonist GuideToPharmacologyInteractions
ADRB2 154 ZINC ION CHEMBL1236970 allosteric modulator GuideToPharmacologyInteractions
ADRB2 154 CICLOPROLOL CHEMBL2110772 antagonist GuideToPharmacologyInteractions
ADRB2 154 METOPROLOL CHEMBL13 antagonist GuideToPharmacologyInteractions
ADRB2 154 SOTALOL CHEMBL471 antagonist GuideToPharmacologyInteractions
ADRB2 154 ISOETHARINE HYDROCHLORIDE CHEMBL1200920 agonist ChemblInteractions
ADRB2 154 PIRBUTEROL ACETATE CHEMBL1200444 agonist ChemblInteractions
ADRB2 154 BITOLTEROL MESYLATE CHEMBL1200405 agonist ChemblInteractions
ADRB2 154 RITODRINE HYDROCHLORIDE CHEMBL1201160 agonist ChemblInteractions
ADRB2 154 ISOETHARINE MESYLATE CHEMBL1201153 agonist ChemblInteractions
ADRB2 154 LEVOBUNOLOL HYDROCHLORIDE CHEMBL1201177 antagonist ChemblInteractions
ADRB2 154 TIMOLOL MALEATE CHEMBL1200870 antagonist ChemblInteractions
ADRB2 154 DOBUTAMINE HYDROCHLORIDE CHEMBL1200418 agonist ChemblInteractions
ADRB2 154 TERBUTALINE SULFATE CHEMBL1160544 agonist ChemblInteractions
ADRB2 154 PENBUTOLOL SULFATE CHEMBL1200363 antagonist ChemblInteractions
ADRB2 154 HYDROXYAMPHETAMINE HYDROBROMIDE CHEMBL1200705 agonist ChemblInteractions
ADRB2 154 CABERGOLINE CHEMBL1201087 binder DrugBank 12388666
ADRB2 154 PHENYLPROPANOLAMINE CHEMBL61006 agonist DrugBank 2881994
ADRB2 154 ISOETHARINE CHEMBL1201213 agonist DrugBank 21948594
ADRB2 154 OLODATEROL CHEMBL605846 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank 20371707

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
ADRB2 rs1042713 AA salmeterol efficacy yes compared to response to montelukast treatment. Children homozygous for the Arg16 variant (genotype AA) were randomized to receive either fluticasone plus montelukast or seretide (salmeterol plus fluticasone) plus placebo for montelukast. School absences, bronchodilator usage, morning cough and wheeze, morning dyspnoea score, night wheeze and dyspnoea scores were all significantly higher in the salmeterol treated group compared to the montelukast treated group. FEV1 % predicted value was not significantly different between the two treatment groups. Genotype AA is associated with decreased response to salmeterol in children with Asthma. 23126384 981499235
ADRB2 rs1042713 A corticosteroids efficacy yes Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG. 26774659 1447680618
ADRB2 rs1042713 A selective beta-2-adrenoreceptor agonists efficacy no Allele A is not associated with response to selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG. 26774659 1447680625
ADRB2 rs1042713 A corticosteroids efficacy no Allele A is not associated with response to corticosteroids in children with Asthma as compared to genotype GG. 26774659 1447680633
ADRB2 rs1042714 G Beta Blocking Agents efficacy no Allele G is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele C. 15861037 613978984
ADRB2 rs1042713 AA salmeterol efficacy yes Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG. 16322642 699639135
ADRB2 rs1042713 A Beta Blocking Agents efficacy no Allele A is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G. 15861037 613978995
ADRB2 rs1800888 T Beta Blocking Agents efficacy no Allele T is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele C. 15861037 613979002
ADRB2 rs2053044 AA + AG ramipril efficacy yes response assessed as reaching mean arterial blood pressure of 107 mmHg or less within 60 days of treatment Genotypes AA + AG is associated with increased response to ramipril in people with Hypertension as compared to genotype GG. 26111150 1444929453
ADRB2 rs1042713 A indacaterol efficacy no Allele A is not associated with response to indacaterol in people with Pulmonary Disease, Chronic Obstructive as compared to allele G. 22158330 827812974
ADRB2 rs1042714 C indacaterol efficacy no Allele C is not associated with response to indacaterol in people with Pulmonary Disease, Chronic Obstructive as compared to allele G. 22158330 827812982
ADRB2 rs1042713 G hydrochlorothiazide efficacy no Allele G is not associated with response to hydrochlorothiazide in people with Essential hypertension as compared to allele A. 14553962 827921283
ADRB2 rs1042714 GG terbutaline metabolism/PK yes Patients with genotype GG being treated with oral terbutaline experience slower desensitization to effects of intravenous terbutaline (increased heart rate and decreased contractility). However, in the long term patients with genotype GG will develop the same level of desensitization as patients with genotypes CC or CG. Genotype GG is associated with increased response to terbutaline in healthy individuals as compared to genotypes CC + CG. 12563174 981345407
ADRB2 rs1042713 AA terbutaline metabolism/PK no Patients with genotype AA being treated with oral terbutaline did not experience a change in the rate of desensitization to effects of intravenous terbutaline (increased heart rate and decreased contractility) when compared to patients with genotypes AG or GG. They also did not experience a change in the level of desensitization. Genotype AA is not associated with increased response to terbutaline in healthy individuals as compared to genotypes AG + GG. 12563174 981345416
ADRB2 rs1042713 AG + GG nifedipine efficacy no This SNP was presented as Arg16Gly. No association between this SNP and effect of nifedipine was found. Genotypes AG + GG are not associated with increased response to nifedipine in people with Hypertension as compared to genotype AA. 19444285 1043858925
ADRB2 rs1042714 CG + GG nifedipine efficacy no This SNP was presented as Gln27Glu. No association between this SNP and effect of nifedipine was found. Genotypes CG + GG are not associated with increased response to nifedipine in people with Hypertension as compared to genotype CC. 19444285 1043858930
ADRB2 rs1042713 AG + GG benazepril efficacy yes Refers to a cohort from Yuexi County in Anhui, China. Carriers of the G allele had a greater decrease in diastolic blood pressure in response to treatment with benazepril compared to AA homozygotes. Patients were treated for 15 days. Both the family-based association test (FBAT) and a multivariate linear regression analysis were used to test for statistical significance. Genotypes AG + GG are associated with increased response to benazepril in people with Essential hypertension as compared to genotype AA. 15554460 982034671
ADRB2 rs1042714 CG + GG enalapril efficacy yes Carriers of the G allele had a greater percent reduction in left ventricular mass index (LVMi) between baseline and after two years of treatment. Genotypes CG + GG are associated with increased response to enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC. 17178264 982036476
ADRB2 rs1042713 AG + GG benazepril efficacy no Refers to a cohort from Huoqiu County in Anhui, China. No significant differences in diastolic or systolic blood pressure change between baseline and after 15 days of treatment were seen between genotypes. Both the family-based association test (FBAT) and a multivariate linear regression analysis were used to test for statistical significance. Genotypes AG + GG are not associated with response to benazepril in people with Essential hypertension. 15554460 982034642
ADRB2 rs1042711 T atenolol efficacy yes Either alone as a SNP or in combination with rs1042713 allele A and rs1042714 allele C as a haplotype. Neither this SNP nor any haplotype combination (haplotypes TGC, CGG, TGG, TAG and CAG were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown). Allele T is not associated with response to atenolol in people with Essential hypertension. 20235788 982044884
ADRB2 rs1042714 CG + GG atenolol efficacy yes Carriers of the G allele had a greater percent reduction in left ventricular mass index (LVMi) between baseline and after two years of treatment. Genotypes CG + GG are associated with increased response to atenolol and enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC. 17178264 982036522
ADRB2 rs1042713 AA carvedilol efficacy no No significant differences in percent change in left ventricular ejection fraction between genotypes was seen. Percent differences calculated between baseline and 12 months of treatment. Genotype AA is not associated with response to carvedilol in people with Heart Failure as compared to genotypes AG + GG. 20352314 982044010
ADRB2 rs1042714 GG carvedilol efficacy yes Patients with the GG genotype had a greater percent increase in left ventricular ejection fraction between baseline and 12 months of treatment, as compared to those with the CC + CG genotypes. Genotype GG is associated with increased response to carvedilol in people with Heart Failure as compared to genotypes CC + CG. 20352314 982044028
ADRB2 rs1042713 A atenolol efficacy yes Either alone as a SNP or in combination with rs1042711 allele T and rs1042714 allele C as a haplotype. Neither this SNP nor any haplotype combination (haplotypes TGC, CGG, TGG, TAG and CAG were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown). Allele A is not associated with response to atenolol in people with Essential hypertension. 20235788 982044891
ADRB2 rs1042714 C atenolol efficacy yes Either alone as a SNP or in combination with rs1042711 allele T and rs1042713 allele A as a haplotype. Neither this SNP nor any haplotype combination (haplotypes TGC, CGG, TGG, TAG and CAG were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown). Allele C is not associated with response to atenolol in people with Essential hypertension. 20235788 982044899
ADRB2 rs1042713 AA methacholine efficacy yes Patients with the AA genotype had lower log PC20 (provocative concentration of methacholine that causes a 20% fall in FEV1) compared to those with the GG genotype, indicating increased airway reactivity and an increased risk of worse asthma outcomes. Please note that this genotype was compared within African Americans, and between African Americans (AA genotype) and Whites (GG genotype). However, allele frequencies were the same between the two ethnicities in this population. African Americans n=45, Whites n=43. Genotype AA is associated with decreased response to methacholine in people with Asthma as compared to genotype GG. 23384627 1183682206
ADRB2 rs1042718 AC fentanyl PD no Volunteers with the AC genotype had a tendency towards a reduced systolic blood pressure following administration of fentanyl. There was no association between this variant and heart rate or QTc. Variant referred to as C523A in the paper. Genotype AC is associated with increased response to fentanyl in healthy individuals as compared to genotype CC. 30281924 1450931709
ADRB2 rs1042718 CC ephedrine metabolism/PK no Outcome was the EP dose equivalent. This is EE = EP + 81.2 x PE. Where EP is ephedrine and PE is phenylephrine. Hypotension was a result of anesthesia after elective neurosurgery. Anesthesia was either propofol/remifentanil or sevoflurane with either remifentanil or fentanyl. Genotype CC is not associated with dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype AA. 26771271 1448263265
ADRB2 rs1042713 AA tiotropium efficacy yes Response defined as improvement on the forced expiratory volume in 1 second (FEV1) by >=15% (or 200 ml) for at least 8 successive weeks after addition of tiotropium to conventional therapy. Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG. 19183167 1184749219
ADRB2 rs1042713 AA phenylephrine dosage yes Women undergoing cesarean delivery. Phenylephrine infusion adjusted based on systolic blood pressure, with phenylephrine infusion totals at 5, 10 and 15 minutes used for analysis. There was an increase of 200 ug in phenylephrine administered to patients at 15 minutes with the AA genotype as compared to those with the GG genotype. Adjusted for maternal body mass index, systolic BP and diastolic BP, neonatal weight, and ethnicity. This SNP was referred to by its amino acid change in the paper: A allele = Arg, G allele =Gly. Genotype AA is associated with increased dose of phenylephrine in women as compared to genotype GG. 25730298 1445297413
ADRB2 rs1042714 CC ephedrine metabolism/PK no Outcome was the EP dose equivalent. This is EE = EP + 81.2 x PE. Where EP is ephedrine and PE is phenylephrine. Hypotension was a result of anesthesia after elective neurosurgery. Anesthesia was either propofol/remifentanil or sevoflurane with either remifentanil or fentanyl. Genotype CC is not associated with dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype GG. 26771271 1448263253
ADRB2 rs1800888 CC ephedrine metabolism/PK no Outcome was the EP dose equivalent. This is EE = EP + 81.2 x PE. Where EP is ephedrine and PE is phenylephrine. Hypotension was a result of anesthesia after elective neurosurgery. Anesthesia was either propofol/remifentanil or sevoflurane with either remifentanil or fentanyl. Genotype CC is not associated with dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype TT. 26771271 1448263259
ADRB2 rs1042719 CC ephedrine metabolism/PK no Outcome was the EP dose equivalent. This is EE = EP + 81.2 x PE. Where EP is ephedrine and PE is phenylephrine. Hypotension was a result of anesthesia after elective neurosurgery. Anesthesia was either propofol/remifentanil or sevoflurane with either remifentanil or fentanyl. Genotype CC is not associated with dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype GG. 26771271 1448263271
ADRB2 rs1042713 A fluticasone propionate efficacy no This variant did not affect patients' responses to recommended asthma therapy with salmeterol and fluticasone propionate. Allele A is not associated with response to fluticasone propionate and salmeterol in people with Asthma as compared to allele G. 17030231 1450935925
ADRB2 rs1042714 C fluticasone propionate efficacy no This variant did not affect patients' responses to recommended asthma therapy with salmeterol and fluticasone propionate. Allele C is not associated with response to fluticasone propionate and salmeterol in people with Asthma as compared to allele G. 17030231 1450935931
ADRB2 rs1042713 A corticosteroids efficacy no Allele A is not associated with response to corticosteroids and Leukotriene receptor antagonists in children with Asthma as compared to genotype GG. 26774659 1447680645
ADRB2 rs1042713 AA ephedrine metabolism/PK no Outcome was the EP dose equivalent. This is EE = EP + 81.2 x PE. Where EP is ephedrine and PE is phenylephrine. Hypotension was a result of anesthesia after elective neurosurgery. Anesthesia was either propofol/remifentanil or sevoflurane with either remifentanil or fentanyl. Genotype AA is associated with decreased dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype GG. 26771271 1448263056
ADRB2 rs1042713 AG + GG benazepril efficacy no Refers to a cohort from Yuexi County in Anhui, China. No significant difference in systolic blood pressure change between baseline and after 15 days of treatment was seen between genotypes. Both the family-based association test (FBAT) and a multivariate linear regression analysis were used to test for statistical significance. Genotypes AG + GG are not associated with response to benazepril in people with Essential hypertension as compared to genotype AA. 15554460 982034790
ADRB2 rs1042714 CG + GG atenolol efficacy yes No significant difference in percent reduction in left ventricular mass index (LVMi) between baseline and after two years of treatment was seen between genotypes. Genotypes CG + GG are not associated with response to atenolol in people with Hypertrophy, Left Ventricular as compared to genotype CC. 17178264 982036485
ADRB2 rs1042713 A salbutamol efficacy no Responders to Salbutamol were defined as patients with percentage reversibility greater than or equal to 12%. Patients demonstrating reversibility < 12% were categorized as non-responders. Rs number in the paper is reported as rs1042716, but the described change matches rs1042713. Not significant by allele, or by co-dominant, dominant, and recessive inheritance. Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G. 26071206 1448259816
ADRB2 rs1042713 GG propranolol efficacy yes all patients had decrease in heart rate and variceal pressure in response to propranolol but decrease was greater in Gly16-GluGln27 group (rs1042713G)(rs1042714) compared to Arg16-Gln27, with compound heterozygotes as intermediate responders. Genotype GG is associated with increased response to propranolol in people with Liver Cirrhosis as compared to genotype AA. 26109805 1447959492
ADRB2 rs1042713 A corticosteroids efficacy no Allele A is not associated with response to corticosteroids, Leukotriene receptor antagonists and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG. 26774659 1447680639
ADRB2 rs1042713 A atenolol efficacy no No significant association between this variant and response to atenolol or metoprolol, as measured by changes in heart rate, in black or Hispanic patients. Allele A is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G. 31090079 1451107121
ADRB2 rs1800888 CT terbutaline efficacy yes There were no homozygous variant subjects. The association was based on the fact that maximal HR increases were higher for WT (p-value=0.016) and QS2c (HR-corrected duration of electromechanical systole) shortening was increased for WT (p=0.022). When the data were analyzed with respect to sex, the authors found that sex was as significantly correlated with these measures as the variant, but that the variant and sex were not correlated with each other. The authors conclude this study supports the decreased survival rate of heterzygous individuals with congestive heart failure. Genotype CT is associated with decreased response to terbutaline in healthy individuals as compared to genotype CC. 11222464 827925168
ADRB2 rs1800888 C fluticasone propionate efficacy no This variant did not affect patients' responses to recommended asthma therapy with salmeterol and fluticasone propionate. Allele C is not associated with response to fluticasone propionate and salmeterol in people with Asthma as compared to allele T. 17030231 1450935937
ADRB2 rs1800888 T atenolol efficacy no No significant association between this variant and response to atenolol or metoprolol, as measured by changes in heart rate, in black or white patients. Note that this variant was not analyzed in black patients from the INVEST cohort as the minor allele was not detected in these patients. Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C. 31090079 1451107302
ADRB2 rs1042714 CC atenolol efficacy yes Patients with the CC genotype had a significantly greater decrease in heart rate than patients with the CG or GG genotypes. Note that this association was only significant in white patients. Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG. 31090079 1451106720
ADRB2 rs1042713 AA atenolol efficacy yes Patients with the AA genotype had a significantly greater decrease in heart rate than patients with the AG or GG genotypes. Note that this association was only significant in white patients. Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG. 31090079 1451107100
ADRB2 rs1042714 G atenolol efficacy no No significant association between this variant and response to atenolol or metoprolol, as measured by changes in heart rate, in black or Hispanic patients. Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C. 31090079 1451107134